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Abstract  
Tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a member 
of the TNF family of cytokines that promotes apoptosis and NF-B activation. Here 
we show that recombinant hu-TRAIL initiates the activation of multiple caspases, the 
loss of mitochondrial transmembrane potential, the cleavage of BID and the 
redistribution of mitochondrial cytochrome c. However, whereas Bcl-2 efficiently 
blocked UV radiation-induced cytochrome c release and consequent apoptosis of 
CEM cells, it failed to do either in the context of TRAIL treatment. Thus, TRAIL 
engages a death pathway that is at least partially routed via the mitochondria, but in 
contrast with other stimuli that engage this pathway, TRAIL induced cytochrome c 
release is not regulated by Bcl-2. 
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1. Introduction 
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a 
member of the TNF family of cytokines that can promote apoptosis and NF-B 
activation by binding to the membrane receptors TRAIL-R1/death receptor (DR)4 
and TRAIL-R2/DR5 [1-8]. Related TRAIL receptors (TRAIL-R3/DcR1/TRID and 
TRAIL-R4/DcR2) have also been described that do not promote apoptosis but may 
function as decoy receptors that reduce the amount of ligand available for binding to 
TRAIL receptors 1 and 2 [5-12].  
 
TRAIL induces apoptosis in a variety of transformed cell lines but is far less effective 
in promoting the death of untransformed cells [13-15]. In addition, in contrast with the 
potent cytotoxicity seen upon administration of agonistic anti-CD95 (APO-1/Fas) 
antibodies in mice [16], the administration of leucine zipper forms of TRAIL is 
relatively non-toxic in vivo [15]. Taken together, these observations suggest that 
TRAIL may have considerable potential as a cancer therapeutic agent. 
The intracellular mechanism of TRAIL-induced apoptosis is unclear at present. 
Predictably, TRAIL-induced apoptosis is caspase-dependent but the repertoire and 
order of caspases activated in response to TRAIL receptor engagement remain ill-
defined [14, 16-18]. Similarly, the adapter molecule(s) that couple the cytoplasmic 
tail of the TRAIL receptors to the death machinery has been the subject of debate [3, 
5, 10, 17, 19, 20]. In particular, studies differ with respect to the role of Fas-
associated protein with death domain (FADD) in transducing TRAIL receptor-initiated 
death signals [3, 5, 10, 17, 19-21]. However, in this context it is relevant to note that 
apoptosis in response to overexpression of TRAIL-R1/DR4 remained intact in 
embryonic fibroblasts from FADD knockout mice, whereas CD95, TNFR1 and DR3-
initiated apoptosis were absent [22]. This suggests that FADD is not essential for 
coupling TRAIL-R1 to the cytoplasmic effectors of apoptosis but does not rule out the 
possibility that this adapter could participate in signalling events initiated by TRAIL-
R2/DR5 and even TRAIL-R1 in other cell types. 
 
In the context of other death receptors such as CD95 and TNFR1, it has been 
established that caspase-8 is the most proximally activated caspase within the death 
signalling pathway [23-25]. Caspase-8 is thought to propagate the death signal 
further in two alternative ways that are not necessarily mutually exclusive: (1) by 
direct proteolytic processing of downstream caspases such as caspase-3 [26-28] 
and (2) by cleaving BID (a Bcl-2 family protein) which then targets the mitochondria 
and promotes release of cytochrome c into the cytosol [29-32]. Upon entry into the 
cytosol, cytochrome c then propagates the caspase cascade by binding to Apaf-1 
and activating its latent caspase-9 activating potential [33-36]. Bcl-2 and Bcl-x have 
been shown to regulate the BID dependent pathway, but it is unclear whether they 
can also intervene in the more direct mitochondria-independent pathway [30-32]. 
 
To explore the mechanism of TRAIL-induced apoptosis, we investigated the range of 
intracellular events that took place in response to TRAIL receptor engagement in the 
Jurkat and CEM T leukaemia cell lines. Exposure of Jurkat cells to recombinant 
TRAIL triggered apoptosis that was accompanied by activation of multiple caspases, 
cleavage of several caspase substrates, loss of mitochondrial transmembrane 
potential, cleavage of BID, release of cytochrome c from the mitochondrial 
intermembrane space and exposure of phosphatidylserine (PS) on the outer leaflet 
of the plasma membrane. Interestingly, although Bcl-2 was effective in attenuating 
BID cleavage, cytochrome c release and consequent apoptosis in response to UV 
irradiation, it failed to do so in the context of TRAIL-induced apoptosis. These data 
suggest that TRAIL engages a Bcl-2-insensitive cell death pathway involving 
mitochondrial cytochrome c release.  
 
 
2. Materials and methods 
 
2.1. Materials 
Annexin V-FITC was purchased from Clontech (Palo Alto, CA, USA), 3,3’-
dihexyloxacarbocyanine iodide (DiOC6) from Molecular Probes (Eugene, OR, USA) 
and Z-Val-Ala-DL-Asp-fluoromethylketone (z-VAD-fmk) from Bachem (UK). Anti-
caspase-3 (CPP32), anti-caspase-7 (Mch-3) and anti-gelsolin monoclonal antibodies 
(mAbs) were purchased from Transduction Laboratories (Lexington, KY, USA), anti-
actin mAb from ICN (UK), anti-caspase-8 (FLICE) and anti-caspase-6 mAbs from 
Pharmingen (San Diego, CA, USA), anti-Fodrin mAb from Chemicon International 
(Temecula, CA, USA), anti-caspase-2 (ICH-1S/L) polyclonal Ab from Santa Cruz 
(Santa Cruz, CA, USA), anti-poly(ADP-ribose) polymerase (PARP) polyclonal Ab 
from Boehringer Mannheim (Germany) and anti-FLAG M2 mAb from Sigma (UK). 
Anti-caspase-9 rabbit polyclonal, anti-FLICE/caspase-8 mAb, anti-BID rat polyclonal 
and anti-cytochrome c rabbit polyclonal were generously provided by Dr Doug Green 
(La Jolla Institute for Allergy and Immunology, San Diego, CA, USA), Dr Marcus 
Peter (German Cancer Research Center, Tumor Immunology Division, Heidelberg, 
Germany), Dr Junying Yuan (Harvard Medical School, Boston, MA, USA) and Dr 
Don Newmeyer (La Jolla Institute for Allergy and Immunology), respectively. 
Recombinant hu-FLAG-TRAIL was produced by co-transfecting COS7 cells with 
pCDNA3.hu-FLAG-TRAIL and pCDNA3.CrmA expression constructs. Serum-free 
supernatants of transfected cells were collected after 1 week, concentrated 20-fold 
and used as stock solution (approximately 50 µg/ml hu-FLAG-TRAIL). The specificity 
of the TRAIL-induced apoptosis was determined by inhibition of TRAIL activity in the 
COS7 cell supernatants with TRAIL-R2-Fc.  
 
 
2.2. Cell culture and induction of apoptosis 
Cells were cultured in RPMI 1640 containing 5% foetal calf serum (FCS). To initiate 
apoptosis, cells were either exposed to a UVB light source for 20 min or incubated 
with indicated dilutions of culture supernatant containing recombinant FLAG-TRAIL, 
in the presence of 50-1000 ng/ml anti-FLAG antibody. Where z-VAD-fmk was used 
to block caspase activity, cells were pre-incubated with the inhibitor for 1 h prior to 
exposure to the apoptosis-promoting stimulus. 
 
 
2.3. Flow cytometry 
Apoptosis was quantitated by staining with annexin V-FITC, which detects PS 
externalisation on the outer leaflet of the plasma membrane, as previously described 
[37]. Briefly, cells were resuspended at 
106/ml in HEPES buffer (10 mM HEPES-NaOH, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 
mM MgCl2, 1.8 mM CaCl2) and incubated for 10 min followed by data collection on a 
FACScan flow cytometer. Changes in mitochondrial membrane potential (m) were 
measured using DiOC6, as follows. Cells were incubated for 30 min at 37ºC in 
culture medium containing 50 nM DiOC6, followed by data collection on a FACScan 
flow cytometer. 
 
 
2.4. SDS-PAGE and Western blotting 
Cells were lysed by incubation for 10 min at 108 cells/ml in ice-cold lysis buffer (50 
mM HEPES-NaOH, pH 7.2, 150 mM NaCl, 5 mM EDTA, 0.1% NP40). Lysates were 
then spun at 20 000xg for 10 min to remove insoluble material. Protein assays (Bio-
Rad, UK) were performed to ensure that equal amounts of protein (120 µg per lane) 
were loaded on each lane of the gel. Proteins were then separated under reducing 
conditions in SDS-PAGE gels, as described previously [36,38]. Separated proteins 
were blotted onto nitrocellulose membrane at 40 mA for 14 h. Blots were blocked for 
1 h in TBST (10 mM Tris-HCl, pH 8, 150 mM NaCl, 0.05% Tween 20) containing 5% 
non-fat dried milk and then probed for 2 h with an appropriate amount of the primary 
antibody diluted in the same buffer.  
Blots were then washed for 30 min in several changes of TBST, followed by probing 
for a further 1 h with the appropriate peroxidase-coupled secondary antibodies 
(Amersham, UK). Bound antibody was detected by enhanced chemiluminescence 
using the Supersignal reagent (Pierce, UK). Blots were erased for re-probing by 
incubation in 0.2 M NaOH for 5 min at room temperature to strip antibodies, followed 
by brief washing in TBST. Blots were then re-blocked and probed with fresh antibody 
as described above.  
 
 
2.5. Cytochrome c release assays 
Cells (1x107) were induced to undergo apoptosis by exposure to UV irradiation or 
FLAG-TRAIL and harvested at times indicated in the appropriate figure legend by 
centrifugation at 800µg for 10 min. Cell pellets were resuspended at 1-2x108 cells/ml 
in mannitol-sucrose extraction buffer containing protease inhibitors (220 mM 
mannitol, 68 mM sucrose, 50 mM PIPES/KOH, pH 7.5, 50 mM KCl, 5 mM EGTA, 2 
mM MgCl2, 1 mM DTT, 1 mM PMSF, 10 Wg/ml leupeptin, 10 µg/ml aprotinin) and 
after 30 min incubation on ice, were disrupted in a Dounce homogeniser with 40 
strokes of a B-type pestle. Cell homogenates were spun at 20 000Ug for 20 min, 
resuspended in the same supernatant and spun again as before. Protein assays 
were performed on the cytosolic fractions using the Bio-Rad reagent (Bio-Rad, UK). 
Equal amounts of each lysate (100-200 µg per lane) were then separated by SDS-
PAGE and immunoblotted for cytochrome c, followed by the re-probing of blots for 
other proteins where appropriate.  
 
 
3. Results and discussion 
 
3.1. TRAIL induces multiple caspase activation events in Jurkat cells 
The exposure of Jurkat T lymphoblastoid cells to recombinant hu-FLAG-TRAIL, in 
the presence of anti-FLAG crosslinking antibody, resulted in a dose-dependent 
increase in cells undergoing morphological features of apoptosis (membrane 
blebbing and DNA condensation; data not shown), as well as exposure of PS on the 
outer leaflet of the plasma membrane, as detected by annexin V binding (Fig. 1A). In 
the presence of limiting amounts of anti-FLAG crosslinking antibody, the lower 
concentrations of FLAG-TRAIL resulted in increased levels of apoptosis (Fig. 1A). 
This is most likely because the crosslinking of FLAG-TRAIL with limiting amounts of 
anti-FLAG antibody becomes less efficient when saturating amounts of ligand are 
present. As expected, TRAIL-induced apoptosis was significantly inhibited in the 
presence of the broad spectrum caspase inhibitor, z-VAD-fmk (Fig. 1B), confirming 
that TRAIL-induced apoptosis is caspase-dependent.  
 
To explore the range of caspase activation events initiated in response to TRAIL 
receptor engagement, we probed cell lysates from TRAIL-treated Jurkat cells with a 
panel of anticaspase antibodies. As illustrated in Fig. 2A, TRAIL treatment resulted in 
the maturation of the zymogen forms of caspase-2, -3, -6, -7, -8 and -9 to their 
corresponding processed forms. A number of well characterised caspase substrates, 
fodrin, gelsolin, PARP and DFF45, were also cleaved in response to TRAIL 
treatment (Fig. 2B). The caspase inhibitor, z-VAD-fmk, blocked essentially all of 
these TRAIL-induced caspase activation events, although a small amount of 
caspase-8 processing was still observed in the presence of this inhibitor suggesting 
that caspase-8 may be the most proximally activated caspase in this context (Fig. 
2A). 
 
 
3.2. TRAIL-initiated mitochondrial events 
Numerous recent studies have implicated the mitochondrion as a key target in the 
program leading to collapse and death of the cell [39-42]. Mitochondria respond to 
numerous apoptosis-promoting signals by releasing pro-apoptotic molecules such as 
cytochrome c and apoptosis-inducing factor into the cytosol [41,43,44]. Mitochondria 
also exhibit a dramatic reduction in transmembrane potential (m), as a result of 
either partial disruption of the outer mitochondrial membrane or the opening of 
discrete membrane channels [39,40,45]. To ask whether TRAIL-initiated apoptosis 
was associated with perturbations in m and the release of mitochondrial 
cytochrome c, we exposed Jurkat cells to TRAIL and assessed changes in v8m and 
cytosolic cytochrome c in the presence or absence of z-VAD-fmk. As shown in Fig. 
3, TRAIL treated Jurkat cells exhibited a dramatic reduction in m that could be 
inhibited by z-VAD-fmk. TRAIL also triggered the caspase-dependent release of 
mitochondrial cytochrome c (Fig. 3B). 
 
In the context of the CD95 and TNF receptor pathways, it was recently demonstrated 
that cytochrome c release is instigated by the Bcl-2 family member, BID [30-32]. In 
response to engagement of the latter death receptors, caspase-8 is rapidly activated 
at the membrane and targets cytosolic BID for proteolytic cleavage. Cleaved BID 
then translocates to the mitochondrial membrane where it triggers cytochrome c 
release via a mechanism that has yet to be elucidated [30-32]. 
 
Thus, we asked whether BID also played a role in the cytochrome c release seen 
during TRAIL-induced death. As illustrated in Fig. 3B,C, TRAIL-induced cytochrome 
c redistribution in Jurkat cells was associated with a dramatic reduction in the levels 
of intact BID (the antibody used did not efficiently recognise the cleaved form of 
BID). The inhibition of caspase activity partially restored the levels of full-length BID, 
in parallel with a concomitant reduction in cytochrome c release (Fig. 3B). To confirm 
that decreases in the levels of intact BID did not reflect a general decrease in cellular 
protein levels as cells underwent apoptosis, a time course experiment was 
performed and levels of BID were compared with actin. As illustrated in Fig. 3C, 
whereas BID levels decreased by almost 50% within 3 h of exposure to TRAIL, actin 
expression levels did not change significantly over the same time course. 
 
 
3.3. Bcl-2 fails to regulate TRAIL-induced apoptosis in CEM cells 
Bcl-2 is capable of repressing apoptosis initiated by numerous death-promoting 
stimuli and is thought to act primarily within the mitochondrial outer membrane where 
it has been shown to regulate cytochrome c release by an unknown mechanism 
[43,44,46]. Limited evidence also suggests that Bcl-2 may be capable of acting 
downstream of this point under certain circumstances [47,48]. It is not known 
whether Bcl-2 is capable of regulating apoptosis initiated by TRAIL receptor ligation. 
 
To explore this question, CEM.neo and CEM.bcl-2 cells were compared with respect 
to their response to TRAIL or exposure to UV radiation. As illustrated in Fig. 4A, Bcl-
2- expressing CEM cells were very resistant to apoptosis initiated by UV irradiation, 
as well as several other stimuli, as previously reported [37,49]. However, Bcl-2 
transfectants were as sensitive to TRAIL as their vector-transfected counterparts, at 
all concentrations tested (Fig. 4B,C). 
 
 
3.4. TRAIL-induced cytochrome c release in CEM cells is not regulated by Bcl-
2 
Because TRAIL-induced apoptosis was associated with the redistribution of 
cytochrome c to the cytosol, an event that is inhibited by Bcl-2 in the context of 
several other pro-apoptotic stimuli, we asked whether the failure of Bcl-2 to regulate 
TRAIL-induced apoptosis could be attributed to a failure to block cytochrome c 
release. Fig. 5 illustrates that Bcl-2 failed to block caspase-8 activation and BID 
cleavage in response to TRAIL receptor engagement on CEM cells, suggesting that 
these events take place upstream of the point of Bcl-2 action, as in the CD95R and 
TNFR pathways. However, whereas Bcl-2 efficiently blocked UV-radiation induced 
cytochrome c release, it failed to do so in cells exposed to TRAIL. These data 
suggest that TRAIL engages a novel pathway leading to cytochrome c release and 
apoptosis that can bypass the protective effects of Bcl-2. We also assessed the Bcl-
2 status in CEM.bcl-2 cells exposed to various concentrations of TRAIL to assess 
whether TRAIL receptor engagement resulted in either phosphorylation, proteolysis 
or downregulation of Bcl-2, however, no overt changes were found by Western 
blotting (data not shown). 
 
Here we have shown that TRAIL engages a cell death pathway that results in 
multiple caspase activation events, the cleavage of the Bcl-2 family member BID, the 
release of cytochrome c and the loss of mitochondrial transmembrane potential. All 
of these events were blocked by caspase inhibitors, suggesting that early caspase 
activation drives the mitochondrial changes that take place in the TRAIL-initiated cell 
death pathway, much in the same way that these events are coordinated in the 
Fas/CD95 and TNFR pathways. However, TRAIL-initiated cytochrome c release and 
consequent apoptosis failed to be regulated by Bcl-2. This contrasts sharply with 
what has been observed with other apoptosis-promoting signals, such as UV 
radiation and staurosporine, that also trigger cytochrome c release [43, 44]. In the 
latter cases, Bcl-2 can block the release of cytochrome c from the mitochondrial 
intermembrane space and consequently confers protection from these agents [43, 
44]. This suggests that TRAIL engages a unique pathway leading to cytochrome c 
release that can bypass the inhibitory effects of Bcl-2, possibly by inactivating the 
latter. These data may partially explain how many tumour cell types are uniquely 
susceptible to the cytotoxic effects of this cytokine. 
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Fig. 1. TRAIL-induced apoptosis is caspase-dependent. A: Jurkat cells were cultured for 6.5 
h in the presence of the indicated dilutions of hu-FLAG-TRAIL supernatant and 50 ng/ml 
crosslinking anti-FLAG antibody, followed by assessment of annexin V-FITC binding by flow 
cytometry. B: Time course of PS externalisation in untreated Jurkat cells or cells cultured in 
the presence of TRAIL (1:1000 dilution, plus 50 ng/ml of anti-FLAG mAb) in the presence or 
absence of 50 µM z-VAD-fmk. Data shown are derived from analyses of 5000 cells at each 
data point and are representative of three separate experiments. 
 
 
Fig. 2. TRAIL-induced activation of multiple caspases and cleavage of caspase substrate 
proteins. A: Jurkat cells were cultured for 4.5 h in medium alone, or in the presence of 50 
ng/ml of hu-FLAGTRAIL plus 50 ng/ml of crosslinking anti-FLAG mAb. Where indicated, z-
VAD-fmk was also added to the medium at a final concentration of 50 µM. Cell lysates were 
then prepared for SDS-PAGE followed by immunoblotting for the detection of the indicated 
caspases.  
Bars represent caspase pro-forms and arrows indicate processed forms. In some cases, in 
order to detect the processed form the lower portions of the blots were overexposed. In 
these cases, the longer exposure is shown as a separate panel. B: Jurkat cells were treated 
as in A, followed by immunoblotting for the indicated caspase substrates. 
  
  
 
Fig. 3. TRAIL-induced mitochondrial changes, cleavage of BID and redistribution of 
cytochrome c are caspase-dependent. A: Jurkat cells were incubated for 4 h either in 
medium alone or in the presence of hu-FLAG-TRAIL (50 ng/ml, plus 50 ng/ml anti-FLAG 
mAb) or hu-FLAGTRAIL plus 50 µM z-VAD-fmk, as indicated. Changes in mitochondrial 
transmembrane potential (m) were measured using DiOC6 uptake in conjunction with flow 
cytometry. B: Jurkat cells were treated as in A, except that cells were incubated for 6 h under 
the indicated conditions. Cytosolic extracts were then made, mitochondria were pelleted and 
extracts were probed for cytochrome c, BID and caspase-3, as indicated. 
 
The arrow indicates the processed form of caspase-3. C: Time course of BID cleavage in 
Jurkat cells cultured in the presence of hu-FLAG-TRAIL (25 ng/ml plus 50 ng/ml anti-Flag 
mAb). After probing for BID, the blot was re-probed for actin to assess protein loadings. For 
quantitation of BID protein levels, densitometry was performed on the blot shown using NIH-
Image software. Data shown are representative of at least three experiments. 
 
  
  
 
Fig. 4. Bcl-2 protects against UV- but not TRAIL-induced apoptosis. CEM cells stably 
transfected with either vector or Bcl-2 expression plasmids were exposed to UV radiation (10 
min) (A) or (B) to hu-FLAG-TRAIL (6.25 ng/ml, plus 50 ng/ml anti-FLAG mAb), followed by 
incubation for 3.5 h. C: CEM.neo and CEM.bcl-2 cells were cultured for 3.5 h in the presence 
of the indicated concentrations of hu-FLAG-TRAIL (50 ng/ml anti-FLAG mAb was included in 
all treatments) followed by assessment of apoptosis. Apoptosis-associated annexin V-FITC 
binding was quantitated by flow cytometry. Data shown are representative of six 
independent experiments.  
  
 
 
Fig. 5. Failure of Bcl-2 to regulate TRAIL-induced cytochrome c release. CEM.neo and 
CEM.bcl-2 cells were either left untreated, were UV-irradiated for 10 min or exposed to 50 
ng/ml hu-FLAGTRAIL (plus 50 ng/ml anti-FLAG mAb), followed by incubation for 7 h. 
Cytosolic extracts were then made followed by probing for the indicated proteins. The lower 
panel of the caspase-8 blot was overexposed to facilitate the detection of the processed 
form of caspase-8. 
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